Future for probiotic science in functional food and dietary supplement development

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 16, Issue 6, 2013, Pages 679-687

  Neef, Alexander ^a   Sanz, Yolanda ^a  

^a INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

Author keywords

bioinformatics; gut microbiota; inflammatory disorders; metagenomics; next generation of probiotics; next generation sequencing; obesity

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 15; PROBIOTIC AGENT; RNA 16S; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA1;

AKKERMANSIA MUCINIPHALA; BACTERIAL STRAIN; BACTEROIDES UNIFORMIS; CLOSTRIDIUM; COLITIS; DIET SUPPLEMENTATION; FAECALIBACTERIUM PRAUSNITZII; FATTY LIVER; FUNCTIONAL FOOD; GENE SEQUENCE; HUMAN; INFLAMMATORY DISEASE; INTESTINE FLORA; METABOLIC DISORDER; MICROBIOME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; RISK REDUCTION; VERRUCOMICROBIA;

AKKERMANSIA MUCINIPHILA; BACTEROIDES UNIFORMIS; CLOSTRIDIA; FAECALIBACTERIUM PRAUSNITZII;

DIET; DIETARY SUPPLEMENTS; FUNCTIONAL FOOD; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA; NUTRITIONAL STATUS; PROBIOTICS;

EID: 84886393898     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328365c258     Document Type: Review

References (48)

1. Bertazzoni Minelli E, Donelli G, Midtvedt T, et al. Probiotics and clinical effects: is the number what counts? J Chemother 2013; 25:193-212.
2. FAO/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a joint FAO/WHO Expert Consultation on Evaluation of Health and nutritional Properties of Probiotics in Food including Powder Milk with live Lactic Acid Bacteria. Córdoba, Argentina; 2001. http://www.who.int/foodsafety/publications/fs- management/en/probiotics.pdf [Accessed 16 September 2013].
3. Meijerink M, Mercenier A, Wells JM. Challenges in translational research on probiotic Lactobacilli: from in vitro assays to clinical trials. Benef Microbes 2013; 4:83-100.
4. Shanahan F, Dinan TG, Ross P, Hill C. Probiotics in transition. Clin Gastroenterol Hepatol 2012; 10:1220-1224.
5. Sanders ME, Guarner F, Guerrant R, et al. An update on the use and investigation of probiotics in health and disease. Gut 2013; 62:787-796.
6. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2013. [Epub ahead of print]
7. Kootte RS, Vrieze A, Holleman F, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14:112-120.
8. Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for faecal microbiota transplantation? Am J Gastroenterol 2012; 107:1452-1459.
9. Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol 2012; 47:1298-1307.
10. Li Q, Wang C, Tang C, et al. Molecular-phylogenetic characterization of the microbiota in ulcerated and nonulcerated regions in the patients with Crohn's disease. PLoS One 2012; 7:e34939.
11. Fujimoto T, Imaeda H, Takahashi K, et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol 2013; 28:613-619.
12. Varela E, Manichanh C, Gallart M, et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2013; 38:151-161.
13. Hansen R, Russell RK, Reiff C, et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol 2012; 107:1913- 1922.
14. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in faecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141:1792-1801.
15. Wu N, Yang X, Zhang R, et al. Dysbiosis signature of faecal microbiota in colorectal cancer patients. Microb Ecol 2013; 66:462-470.
16. Graessler J,Qin Y, Zhong H, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J 2012. [Epub ahead of print]
17. Wong VW, Tse CH, Lam TT, et al. Molecular characterization of the faecal microbiota in patients with nonalcoholic steatohepatitis: a longitudinal study. PLoS One 2013; 8:e62885.
18. Candela M, Rampelli S, Turroni S, et al. Unbalance of intestinal microbiota in atopic children. BMC Microbiol 2012; 12:95.
19. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489:242-249.
20. Miquel S, Martín R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 2013; 16:255-261.
21. Qiu X, Zhang M, Yang X, et al. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis 2013. [Epub ahead of print]. doi: S1873- 9946(13)00141-4.
22. Atarashi K, Tanoue T, Oshima K, et al. T(reg) induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013; 500:232-236.
23. Belzer C, de Vos WM. Microbes inside - from diversity to function: the case of Akkermansia. ISME J 2012; 6:1449-1458. A review on this mucus colonizer emerging focus of probiotic research and possible key player in the intestinal interaction network.
24. Ouwerkerk JP, de Vos WM, Belzer C. Glycobiome: bacteria and mucus at the epithelial interface. Best Pract Res Clin Gastroenterol 2013; 27:25-38.
25. Sanz Y, Rastmanesh R, Agostonic C. Understanding the role of gut microbes and probiotics in obesity: how far are we? Pharmacol Res 2013; 69:144-155.
26. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2012; 464:59-65.
27. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013; 110:9066-9071.
28. Hansen CH, Krych L, Nielsen DS, et al. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 2012; 55:2285-2294.
29. Hansen CH, Holm TL, Krych ?, et al. Gut microbiota regulates NKG2D ligand expression on intestinal epithelial cells. Eur J Immunol 2013; 43:447-457.
30. Fava F, Gitau R, Griffin BA, et al. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. Int J Obes (Lond) 2013; 37:216-223.
31. Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, calorie load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94:58-65.
32. Sánchez E, De Palma G, Capilla A, et al. Influence of environmental and genetic factors linked to celiac disease risk on infant gut colonization by Bacteroides species. Appl Environ Microbiol 2011; 77:5316-5323.
33. Owen CG, Martin RM, Whincup PH, et al. Effect of infant feeding on the risk of obesity across the life course: a quantitative review of published evidence. Pediatrics 2005; 115:1367-1377.
34. Gauffin Cano P, Santacruz A, Moya A , Sanz Y. Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with highfat- diet induced obesity. PLoS One 2012; 7:e41079.
35. Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 2013; 7:880-884.
36. Relman DA. Learning about who we are. Nature 2012; 486:194-195.
37. Morgan XC, Huttenhower C. Chapter 12: human microbiome analysis. PLoS Comput Biol 2012; 8:e1002808.
38. Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome: current knowledge, challenges, and future directions. Translat Res 2012; 160:246-257.
39. Kelsen JR, Wu GD. The gut microbiota, environment and diseases of modern society. Gut Microbes 2012; 3:374-382.
40. Proctor LM. The human microbiome project in 2011 and beyond. Cell Host Microbes 2011; 10:287-291.
41. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490:55.
42. The HMP consortium. Huttenhower C, Gevers D, Knight R, et al. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-214.
43. The HMP consortium. Methé BA, Nelson KE, Pop M, et al. A framework for human microbiome research. Nature 2012; 486:215-221.
44. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012; 486:222-227.
45. Fodor AA, DeSantis TZ,Wylie KM, et al. The 'most wanted' taxa from the human microbiome for whole genome sequencing. PLoS One 2012; 7:e41294.
46. Frémont M, Coomans D, Massart S, De Meirleir K. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/ chronic fatigue syndrome patients. Anaerobe 2013; 22:50-56.
47. Xiong X, Frank DN, Robertson CE, et al. Generation and analysis of a mouse intestinal metatranscriptome through Illumina based RNA-sequencing. PLoS One 2012; 7:e36009.
48. Schwartz S, Friedberg I, Ivanov IV, et al. A metagenomic study of dietdependent interaction between gut microbiota and host in infants reveals differences in immune response. Genome Biol 2012; 13:r32.